MVP completes European Distribution deal with Mundipharma
14 September 2015
Mundipharma and Medical Developments International announce a new alliance for the commercialisation of Penthrox® in Europe
Cambridge, UK and Victoria, Australia, September, 14th 2015 – Mundipharma International Corporation Limited (Mundipharma) and Medical Developments International Limited (ASX: MVP) today announced that they have entered into a License, Development and Commercialisation Agreement for Penthrox® (low dose methoxyflurane) in Europe, as a self-inhaled analgesic for the treatment of emergency pain.
For more information please click on the following link – MVP completes European Distribution deal with Mundipharma